Berapa harga CARsgen Therapeutics Holdings Limited (2171)

Harga CARsgen Therapeutics Holdings Limited (2171) adalah $1.72

Apa kapitalisasi pasar CARsgen Therapeutics Holdings Limited (2171)

Kapitalisasi pasar CARsgen Therapeutics Holdings Limited (2171) adalah $981.92M

Pendapatan CARsgen Therapeutics Holdings Limited (2171)

CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in Shanghai, China, in 2014, focuses on the discovery, development, and commercialization of advanced chimeric antigen receptor T (CAR-T) cell therapies. The company's efforts are directed toward treating various hematological malignancies and solid tumors across China and the United States. Its robust pipeline includes several key candidates: CT053, an autologous CAR-T product, is currently in a pivotal Phase II trial in China for relapsed/refractory multiple myeloma. Additionally, CT041, another autologous CAR-T, is undergoing Phase Ib/II clinical trials for advanced gastric/gastroesophageal junction and pancreatic cancers in China, and Phase Ib trials for comparable indications in the U.S. CARsgen is also advancing CT011, an autologous CAR-T candidate, through Phase I for patients with Glypican-3 positive advanced hepatocellular carcinoma, and CT032, an autologous CAR-T, in Phase I/II for B cell Non-Hodgkin's lymphoma in China. Furthermore, its pipeline features AB011, a humanized monoclonal antibody in Phase I for CLDN18.2 positive solid tumors in China, as well as CT017, an autologous Glypican-3-targeted CAR-T for hepatocellular carcinoma, and other promising therapies for solid tumors.

Tahun	Laba	Mengubah
Tidak cukup data untuk tanggal yang disediakan.

Tahun

Laba

Mengubah

Tidak cukup data untuk tanggal yang disediakan.

Perusahaan	Laba	Perbedaan Laba	Negara
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
CSL Limited CSL.AX	$-4.02B	-	AU
Moderna, Inc. MRNA.US	$-3.09B	-	US
Lonza Group AG LONN.SW	-	-	CH

Perusahaan

Laba

Perbedaan Laba

Negara